Neutralization escape variant of West Nile virus associated with altered peripheral pathogenicity and differential cytokine profile

Virus Research

Volumn 158, Issue 1-2, 2011, Pages 130-139

  Sapkal, G N ^a   Harini, S ^a   Ayachit, V M ^a   Fulmali, P V ^a   Mahamuni, S A ^a   Bondre, V P ^a   Gore, M M ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Cytokines; Pathogenesis; Replication; Variants; WNV

Indexed keywords

BETA INTERFERON; CYTOKINE; ENVELOPE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PROLINE; SERINE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; IN VITRO STUDY; INOCULATION; MOUSE; NONHUMAN; PERITONEUM EXUDATE; PRIORITY JOURNAL; VIROGENESIS; VIRUS ENCEPHALITIS; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CRICETINAE; CYTOKINES; ENCEPHALITIS, VIRAL; IMMUNE EVASION; MICE; MUTATION, MISSENSE; SURVIVAL ANALYSIS; SWINE; VIRULENCE; WEST NILE VIRUS;

ANIMALIA; CRICETINAE; MURINAE; SUS; WEST NILE VIRUS;

EID: 79956329810     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.03.023     Document Type: Article

References (53)

1. Beasley D.W., Li L., Suderman M.T., Barrett A.D.T. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 2002, 296:17-23.
2. Beasley D.W.C., Whiteman M.C., Zhang S., Huang C.Y.H., Schneider B.S., Smith D.R., Gromowski G.D., Higgs S., Kinney R.M., Barrett A.D.T. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 2005, 79:8339-8347.
3. Ben-Nathan I.D., Huitinga I., Lustig S., van Rooijen N., Kobiler D. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol. 1996, 141:459-469.
4. Biswas S.M., Ayachit V.M., Sapkal G.N., Mahamuni S.A., Gore M.M. Japanese encephalitis virus produces a CD4-Th2 response and associated immunoprotection in an adoptive transfer murine model. J. Gen. Virol. 2009, 90:818-826.
5. Bondre V.P., Jadi R.S., Mishra A.C., Yergolkar P.N., Arankalle V.A. West Nile virus isolates from India: evidence for a distinct genetic lineage. J. Gen. Virol. 2007, 88:875-884.
6. Bunning M.L., Bowen R.A., Cropp B., Sullivan K., Davis B., Komar N., Godsey M., Baker D., Hettler D., Holmes D., Mitchell C.J. Experimental infection of horses with West Nile virus and their potential to infect mosquitoes and serve as amplifying hosts. Ann. N Y Acad. Sci. 2001, 951:338-339.
7. Byrne S.N., Halliday G.M., Johnston L.J., King N.J. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J. Invest. Dermatol. 2001, 117(3):702-709.
8. Cecilia D., Gadkari D.A., Kedarnath N., Ghosh S.N. Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain. J. Gen. Virol. 1988, 69:2741-2747.
9. Cecilia D., Gould E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization resistant variants. Virology 1991, 181:70-77.
10. Cernescu C., Ruţǎ S.M., Târdei G., Grancea C., Moldoveanu L., Spulbǎr E., Tsai T. A high number of severe neurologic clinical forms during an epidemic of West Nile virus infection. Rom. J. Virol. 1997, 48:13-25.
11. Chambers T.J., Halevy M., Nestorowicz A., Rice C.M., Lustig S. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J. Gen. Virol. 1998, 79:2375-2380.
12. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 1999, 73:3095-3101.
13. Charlier N., Leyssen P., Paeshuyse J., Drosten C., Schmitz H., Van Lommet A., De Clercq E., Neyts J. Infection of SCID mice with Montann Myotis Leukoencephalitis virus as a model for flavivirus encephalitis. J. Gen. Virol. 2002, 83:1887-1896.
14. Churdboonchart V., Bhamarapravati N., Peampramprecha S., Sirinavin S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1991, 44:481-493.
15. Dewasthaly S., Ayachit V.M., Sarthi S.A., Gore M.M. Monoclonal antibody raised against envelope glycoprotein peptide neutralizes Japanese encephalitis virus. Arch. Virol. 2001, 146:1427-1435.
16. George S., Gourie-Devi M., Rao J.A., Prasad S.R., Pavri K.M. Isolation of West Nile virus from the brains of children who had died of encephalitis. Bull. World Health Organ. 1984, 62:879-882.
17. Gore M.M., Gupta A.K., Ayachit V.M., Athawale S.S., Ghosh S.N., Banerjee K. Selection of neutralization escape variant strains of Japanese encephalitis virus using monoclonal antibody. Indian J. Med. Res. 1990, 91:231-233.
18. Garcia-Tapia D., Loiacono C.M., Kleiboeker S.B. Replication of West Nile virus in equine peripheral blood mononuclear cells. Vet. Immunol. Immunopathol. 2006, 110:229-244.
19. Halevy M., Akov Y., Ben-Nahan D., Kobiler D., Lachmi B., Lustig S. Loss of active neuroinvasiveness in attenuated strain of West Nile virus; pathogenicity in immunocompetent and SCID mice. Arch. Virol. 1994, 137:355-370.
20. Hasegawa H., Yoshida M., Shiosaka T., Fujita S., Kobayashi Y. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology 1992, 191:158-165.
21. Hayes E.B., Sejvar J.J., Zaki S.R., Lanciotti R.S., Bode A.V., Campbell G.L. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 2005, 11:1174-1179.
22. Holzmann H., Heinz F.X., Mandl C.W., Guirakhoo F., Kunz C. A single amino acid substitution in the envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 1990, 64:5156-5159.
23. Ishak H., Takegami T., Kamimura K., Funada H. Comparative sequences of two type 1 dengue virus strains possessing different growth characteristics in vivo. Microbiol. Immunol. 2001, 45:327-331.
24. Jamgaonkar A.V., Yergolkar P.N., Geevarghese G., Joshi G.D., Joshi M.V., Mishra A.C. Serological evidence for Japanese encephalitis virus and West Nile virus infections in water frequenting and terrestrial wild birds in Kolar District, Karnataka State, India. A retrospective study. Acta Virol. 2003, 47:185-188.
25. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J. Virol. 1999, 73:783-786.
26. Kanai R., Kar K., Anthony K., Gould L.H., Ledizet M., Fikrig E., Marasco W.A., Koski R.A., Modis Y. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 2006, 80:11000-11008.
27. Kaufman B.M., Summers P.L., Dubois D.R., Echels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1987, 36:427-434.
28. Kimura-Kuroda An J.J., Hirabayashi Y., Yasui K. Development of a novel model for Dengue virus infection. Virology 1999, 263:70-77.
29. Leyssen P., Drosten C., Paning M., Charlier N., Paeshuyse J., De Clarcq E., Neyts J. Interferons, interferon inducers and interferon ribavirin in treatment of flavivirus induced encephalitis in mice. Antimicrob. Agents Chemother. 2003, 47:777-782.
30. Li J., Bhuvanakantham R., Howe J., Ng M.L. The glycosylation site in the envelope protein of West Nile virus (Sarafend) plays an important role in replication and maturation processes. J. Gen. Virol. 2006, 87:613-622.
31. Lindsey N.P., Kuhn S., Campbell G.L., Hayes E.B. West Nile virus neuroinvasive disease incidence in the United States, 2002-2006. Vector Borne Zoonotic Dis. 2008, 8:35-39.
32. Lucas M., Mashim U.T., Frenkiel M.P., Simon Chazottes D., Montagutell X., Ceccaldi P.E., Guenet J.L., Despres P. Infection of mouse neurons by West Nile virus is modulated by the interferon-inducible 2'5' oligoadenylate synthetase 1b protein. Immunol. Cell Biol. 2003, 81:230-236.
33. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 2004, 10(12 Suppl):S98-109.
34. Malkinson M., Banet C., Weisman Y., Pokamunski S., King R., Drouet M.T., Deubel V. Introduction of West Nile virus in the Middle East by migrating white storks. Emerg. Infect. Dis. 2002, 8:392-397.
35. Murata R., Eshita Y., Maeda A., Maeda J., Akita S., Tanaka T., Yoshii K., Kariwa H., Umemura T., Takashima I. Glycosylation of the West Nile Virus envelope protein increases in vivo and in vitro viral multiplication in birds. Am. J. Trop. Med. Hyg. 2010, 82:696-704.
36. Murgue B., Zeller H., Deubel V. The ecology and epidemiology of West Nile virus in Africa, Europe and Asia. Curr. Top. Microbiol. Immunol. 2002, 267:195-221.
37. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 2006, 80:11467-11474.
38. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005, 11:522-530.
39. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.-E., Olshevsky U., Fremont D.H., Pierson T.C., Diamond M.S. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 2006, 80:12149-12159.
40. Pletnev A.G., Bray M., Lai C.-J. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 1993, 67:4956-4963.
41. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hygiene 1938, 27:493-497.
42. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2Å resolution. Nature 1995, 375:291-298.
43. Samuel M.A., Diamond M.S. Type I IFN protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 2005, 79:13350-13361.
44. Scherret J.H., Mackenzie J.S., Khromykh A.A., Hall R.A. Biological significance of glycosylation of the envelope protein of Kunjin virus. Ann. N. Y. Acad. Sci. 2001, 951:361-363.
45. Sejvar J.J., Bode A.V., Marfin A.A., Campbell G.L., Pape J., Biggerstaff B.J., Petersen L.R. West Nile Virus-associated flaccid paralysis outcome. Emerg. Infect. Dis. 2006, 12:514-516.
46. Shirato K., Miyoshi H., Goto A., Ako Y., Ueki T., Kariwa H., Takashima I. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol. 2004, 85:3637-3645.
47. Samuel M.A., Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 2005, 79:13350-13361.
48. Sultana H., Foellmer H., Neelakanta G., Oliphant T., Engle M., Ledizet M., Krishnan M., Bonafe N., Anthony K.G., Wayne A.M., Paul Kaplan, Ruth R.M., Diamond M.S., Raymond A.K., Fikrig E. Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J. Immunol. 2009, 183:650-660.
49. Umrigar M.D., Pavri K.M. Comparative biological studies on Indian strains of West Nile virus isolated from different sources. Indian J. Med. Res. 1977, 65:596-602.
50. Umrigar M.D., Pavri K.M. Comparative serological studies on Indian strains of West Nile virus isolated from different sources. Indian J. Med. Res. 1977, 65:603.
51. Valdes S.K., Alvarez M., Pupo M., Vaózquez S., Rodriguez R., Guzmaón M.G. Human dengue antibodies against structural and nonstructural proteins. Clin. Diagn. Lab. Immunol. 2000, 7:856-857.
52. Vorndam V., Mathews J.H., Barrett A.D., Roshrig J.T., Trent D.W. Molecular and biological characterization of a non glycosylated isolate of St. Louis encephalitis virus. J. Gen. Virol. 1993, 74:2653-2660.
53. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 2004, 10:1366-1373.